Literature DB >> 5420239

Clofibrate, serum enzymes, and muscle pain.

A F Smith, W G Macfie, M F Oliver.   

Abstract

Serum creatine kinas (C.K.), aspartate amino-transferase (G.O.T.), and alkaline phosphatase (A.P.) activities were measured in 211 men with serum cholesterol concentrations in the upper one-third of the normal distribution. Of these, 110 were receiving clofibrate and 101 were given identical capsules containing olive oil. These investigations were also carried out on 85 healthy men with low serum cholesterol levels not receiving clofibrate.No differences were observed in C.K. and G.O.T. activities between any of these groups; A.P. was significantly lower in the clofibrate-treated group. No significant alterations in C.K. occurred during serial observations made in 15 patients with ischaemic heart disease over a period of five months. No instance of myalgia or muscle stiffness was recorded in 452 men who had received clofibrate for one year.It is concluded that raised C.K. and G.O.T. concentrations and the occurrence of myalgia are uncommon accompaniments of clofibrate treatment.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5420239      PMCID: PMC1699923          DOI: 10.1136/bmj.2.5701.86

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  THE EFFECTS OF ATROMID ON SERUM LIPIDS, PROTEINS AND SOME LIVER FUNCTION TESTS IN HYPERCHOLESTEROLAEMIC PATIENTS.

Authors:  A KONTTINEN; J PALOHEIMO
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec

2.  A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases.

Authors:  S REITMAN; S FRANKEL
Journal:  Am J Clin Pathol       Date:  1957-07       Impact factor: 2.493

3.  Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine.

Authors:  P R KIND; E J KING
Journal:  J Clin Pathol       Date:  1954-11       Impact factor: 3.411

4.  Reduction of serum-lipid and uric-acid levels by an orally active androsterone.

Authors:  M F OLIVER
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

5.  Acute muscular syndrome associated with administration of clofibrate.

Authors:  T Langer; R I Levy
Journal:  N Engl J Med       Date:  1968-10-17       Impact factor: 91.245

6.  An automated p-nitrophenylphosphate serum alkaline phosphatase procedure for the AutoAnalyzer.

Authors:  S Morgenstern; G Kessler; J Auerbach; R V Flor; B Klein
Journal:  Clin Chem       Date:  1965-09       Impact factor: 8.327

7.  The primary preventiono of ischemic heart disease by means of Atromid-S (clofibrate).

Authors:  M F Oliver
Journal:  Bull N Y Acad Med       Date:  1968-08
  7 in total
  9 in total

1.  Clofibrate-induced myopathy in the rat.

Authors:  H Teräväinen; A Larsen; M Hillbom
Journal:  Acta Neuropathol       Date:  1977-08-16       Impact factor: 17.088

2.  Clofibrate disposition in renal failure and acute and chronic liver disease.

Authors:  R Gugler; J W Kürten; C J Jensen; U Klehr; J Hartlapp
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

3.  The effect of lysergic acid di-ethylamide on serum creatine kinase levels.

Authors:  T Harding
Journal:  Psychopharmacologia       Date:  1974

4.  Effects of poisoning on serum enzyme activities, coagulation, and fibrinolysis.

Authors:  N Wright; A R Clarkson; S S Brown; V Fuster
Journal:  Br Med J       Date:  1971-08-07

5.  Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.

Authors:  A Bardosi; P Scheidt; H H Goebel
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

6.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

Review 7.  PPARs and pain.

Authors:  Bright N Okine; Jessica C Gaspar; David P Finn
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 8.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb

Review 9.  Combination drug therapy for combined hyperlipidemia.

Authors:  J R Guyton
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 3.955

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.